EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer

Kévin Hébert, Paul Bodin-Cufi, Cyril Fersing, Emmanuel Deshayes

European Urology Focus · 2024

DOI: 10.1016/j.euf.2024.07.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2024. Verfasst von Kévin Hébert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadioisotopesRadiopharmaceuticalsHumansMaleLutetiumNeoplasm MetastasisHeterocyclic Compounds, 1-RingDipeptidesMolecular Targeted Therapy

Stichwörter der Autor:innen

Metastatic prostate cancerProstate-specific membrane antigenTargeted radionuclide therapy

Substanzen

RadioisotopesRadiopharmaceuticalsLutetiumHeterocyclic Compounds, 1-RingLutetium-177Dipeptides

Autor:innen und Institutionen

  • Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
  • Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut des Biomolécules Max Mousseron, University of Montpellier, Montpellier, France.
  • Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; INSERM U1194, Institut de Recherche en Cancérologie de Montpellier, University of Montpellier, Mon…

Zitieren

APA

Hébert, K., Bodin-Cufi, P., Fersing, C., & Deshayes, E. (2024). New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2024.07.016

Vancouver

Hébert K, Bodin-Cufi P, Fersing C, Deshayes E. New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. European Urology Focus. 2024. doi:10.1016/j.euf.2024.07.016

BibTeX
@article{Hbert2024,
  author = {Hébert, Kévin and Bodin-Cufi, Paul and Fersing, Cyril and Deshayes, Emmanuel},
  title = {New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer},
  journal = {European Urology Focus},
  year = {2024},
  doi = {10.1016/j.euf.2024.07.016}
}
Kostenlos starten →